Author:
Eijsink Job F. H.,Al Khayat Mohamed N. M. T.,Boersma Cornelis,ter Horst Peter G. J.,Wilschut Jan C.,Postma Maarten J.
Abstract
Abstract
Background
The prevalence of diagnosed chronic hepatitis C virus (HCV) infection among pregnant women in the Netherlands is 0.26%, yet many cases remain undiagnosed. HCV screening and treatment of pregnant HCV carriers could reduce the burden of disease and limit vertical transmission from mother to child. We assessed the impact of HCV screening and subsequent treatment with new direct-acting antivirals (DAAs) among pregnant women in the Netherlands.
Methods
An HCV natural history Markov transition state model was developed, to evaluate the public-health and economic impact of HCV screening and treatment. Besides all 179,000 pregnant women in the Netherlands (cohort 1), we modelled 3 further cohorts: all 79,000 first-time pregnant women (cohort 2), 33,000 pregnant migrant women (cohort 3) and 16,000 first-time pregnant migrant women (cohort 4). Each cohort was analyzed in various scenarios: i no intervention, i.e., the current practice, ii screen-and-treat, i.e., the most extensive approach involving treatment of all individuals found HCV-positive, and iii screen-and-treat/monitor, i.e., a strategy involving treatment of symptomatic (F1–F4) patients and follow-up of asymptomatic (F0) HCV carriers with subsequent treatment only at progression.
Results
For all cohorts, comparison between scenarios (ii) and (i) resulted in ICERs between €9,306 and €10,173 per QALY gained and 5 year budget impacts varying between €6,283,830 and €19,220,405. For all cohorts, comparison between scenarios (iii) and (i) resulted in ICERs between €1,739 and €2,749 per QALY gained and budget impacts varying between €1,468,670 and €5,607,556. For all cohorts, the ICERs (scenario iii versus ii) involved in delayed treatment of asymptomatic (F0) HCV carriers varied between €56,607 and €56,892, well above the willingness-to-pay (WTP) threshold of €20,000 per QALY gained and even above a threshold of €50,000 per QALY gained.
Conclusion
Universal screening for HCV among all pregnant women in the Netherlands is cost-effective. However, it would be reasonable to consider smaller risk groups in view of the budget impact of the intervention.
Publisher
Springer Science and Business Media LLC
Subject
Health Policy,Economics, Econometrics and Finance (miscellaneous)
Reference53 articles.
1. Willemse, S.B., Razavi-Shearer, D., Zuure, F.R., Veldhuijzen, I.K., Croes, E.A., van der Meer, A.J., et al.: The estimated future disease burden of hepatitis C virus in the Netherlands with different treatment paradigms. Neth. J Med. 73(9), 417–431 (2015)
2. Seeff, L.B.: Natural history of chronic hepatitis C. Hepatology (2002). https://doi.org/10.1053/jhep.2002.36806
3. Grebely, J., Page, K., Sacks-Davis, R., van der Loeff, M.S., Rice, T.M., Bruneau, J., et al.: The effects of female sex, viral genotype, and IL28B genotype on spontaneous clearance of acute hepatitis C virus infection. Hepatology (2014). https://doi.org/10.1002/hep.26639
4. Muir, A.J., Naggie, S.: Hepatitis C virus treatment: is it possible to cure all hepatitis C virus patients? Clin. Gastroenterol. Hepatol. (2015). https://doi.org/10.1016/j.cgh.2015.07.015
5. Tovo, P.A., Newell, M.L., Coll, O., de Tejada, B.M., Lanari, M., Bosi, I., et al.: Effects of mode of delivery and infant feeding on the risk of mother-to-child transmission of hepatitis C virus: European Paediatric Hepatitis C Virus Network. Br. J. Obstet. Gynaecol. (2001). https://doi.org/10.1016/S0306-5456(00)00088-7